Molecular Templates, Inc.

NasdaqCM:MTEM Rapporto sulle azioni

Cap. di mercato: US$2.6m

Molecular Templates Gestione

Gestione criteri di controllo 2/4

Molecular Templates Il CEO è Eric Poma, nominato in Jan2009, e ha un mandato di 15.83 anni. la retribuzione annua totale è $ 857.77K, composta da 72.4% di stipendio e 27.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.28% delle azioni della società, per un valore di $ 7.43K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 7.3 anni.

Informazioni chiave

Eric Poma

Amministratore delegato

US$857.8k

Compenso totale

Percentuale dello stipendio del CEO72.4%
Mandato del CEO15.8yrs
Proprietà del CEO0.3%
Durata media del management1.3yrs
Durata media del Consiglio di amministrazione7.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Oct 10
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise

Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Aug 17
Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Jul 30
Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Apr 03
Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Dec 20
Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Apr 17
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Aug 14
Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Aug 11

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Apr 29
Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Dec 30
Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Nov 25
Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

Sep 22
Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Aug 15
News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Mar 21
Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Feb 21
Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Jan 26
Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Eric Poma rispetto agli utili di Molecular Templates?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$858kUS$621k

-US$8m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$600k

-US$93m

Sep 30 2022n/an/a

-US$81m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$577k

-US$83m

Sep 30 2021n/an/a

-US$101m

Jun 30 2021n/an/a

-US$94m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020US$5mUS$560k

-US$105m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$107m

Mar 31 2020n/an/a

-US$85m

Dec 31 2019US$2mUS$515k

-US$69m

Sep 30 2019n/an/a

-US$60m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$4mUS$500k

-US$30m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$36m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$3mUS$448k

-US$24m

Compensazione vs Mercato: La retribuzione totale di Eric ($USD 857.77K ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 646.00K ).

Compensazione vs guadagni: La retribuzione di Eric è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Eric Poma (52 yo)

15.8yrs

Mandato

US$857,769

Compensazione

Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Eric Poma
CEO, Chief Scientific Officer & Director15.8yrsUS$857.77k0.28%
$ 7.4k
Jason Kim
President1.8yrsUS$579.24k0.097%
$ 2.6k
Kristen Quigley
Chief Operating Officer1.3yrsNessun datoNessun dato
Grace Kim
Chief Strategy Officer & Head of IR1.3yrsNessun datoNessun dato
Michelle Iwamoto-Fan
Senior Vice President & General Counselless than a yearNessun datoNessun dato
Joseph Phillips
Senior VP & Head of CMC Developmentno dataNessun datoNessun dato
Chris Moore
Senior VP and Head of Preclinical Development & Translational Medicineless than a yearNessun datoNessun dato

1.3yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di MTEM non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Eric Poma
CEO, Chief Scientific Officer & Director7.3yrsUS$857.77k0.28%
$ 7.4k
Michel Klein
Member of Scientific Advisory Boardno dataNessun datoNessun dato
David Hoffmann
Independent Director7.3yrsUS$59.29k0%
$ 0
Harold Selick
Independent Chairman7.3yrsUS$87.29k0.041%
$ 1.1k
Kevin Lalande
Independent Director7.3yrsUS$54.29k0%
$ 0
Corazon Sanders
Independent Director4.9yrsUS$49.29k0%
$ 0
Burkhard Jansen
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Neil Berinstein
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Gabriela Gruia
Director2.7yrsUS$561.35k0%
$ 0

7.3yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MTEM sono considerati esperti (durata media dell'incarico 7.3 anni).